Associated tags: Migraine, Indometacin, Neurology, Cluster headache, ECOR, ElectroCore, Pharmaceutical industry, A luta continua, NVN
Locations: NEW JERSEY, GEORGIA, TEXAS, ROCKAWAY, NJ, US
ROCKAWAY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results.
Key Points:
- Total operating expenses in the first quarter of 2024 were approximately $8.4 million as compared to $8.5 million in the first quarter of 2023.
- Research and development expense in the first quarter of 2024 was $399,000 as compared to $1,800,000 in the first quarter of 2023.
- Adjusted EBITDA net loss in the first quarter of 2024 was $3.1 million as compared to adjusted EBITDA net loss of $5.1 million in the first quarter of 2023.
- These improved results are also primarily due to the 96% increase in first quarter 2024 net sales over the first quarter of 2023.
ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.
Key Points:
- ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.
- The RSUs were granted as an inducement material to Mr. Melnikoff’s commencement of employment and were granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).
- 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Melnikoff’s continued employment by the Company on the applicable vesting date.
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.
Key Points:
- ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.
- Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand.
- Truvaga Plus is engineered to seamlessly integrate into daily routines and is a holistic and convenient solution to manage stress and enhance overall wellbeing.
- “I am thrilled to announce the launch of our next generation, app-enabled general wellness product, Truvaga Plus,” stated Dan Goldberger, CEO of electroCore.
Vagus nerve,
Central nervous system,
Fibromyalgia,
Patent,
TBI,
Anxiety,
Software,
United States patent law,
ElectroCore,
PTSD,
Medical device ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
Key Points:
- ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
- The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
US Patent No.
- The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
- The electrical impulses are bursts of 2 to 20 sinusoidal pulses.
Retrieved on:
Wednesday, March 13, 2024
ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2023 financial results.
Key Points:
- Gross margin was 83% and 81% for the years ended December 31, 2023 and 2022, respectively.
- Total operating expenses for the full year of 2023 were approximately $32.5 million, as compared to $29.9 million for the full year of 2022.
- Research and development expense for the full year of 2023 was $5.3 million as compared to $5.5 million for the full year of 2022.
- Adjusted EBITDA net loss in the fourth quarter of 2023 was a loss of $2.9 million as compared to a loss of $4.7 million in the fourth quarter of 2022.
Please contact Roth MKM to schedule a 1x1 meeting.
Key Points:
- Please contact Roth MKM to schedule a 1x1 meeting.
- In addition, Dan Goldberger, CEO of electroCore, Inc. is scheduled to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8 – 11, 2024.
- Mr. Goldberger will give a company presentation on April 8th at 3:00 pm and will host 1x1 investor meetings throughout the conference.
- Please contact Needham to schedule a 1x1 meeting.
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024.
Key Points:
- ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024.
- Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Retrieved on:
Tuesday, February 6, 2024
C-reactive protein,
Patent,
Virus,
COVID,
Disorder,
Vagus nerve,
Patient,
Blood,
United States patent law,
Coronaviridae,
ElectroCore ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
Key Points:
- ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
- U.S. Patent No.
- 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases Associated With Viruses” generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
Key Points:
- ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
- U.S. Patent No.
- 11,865,329 entitled “Vagal Nerve Stimulation for Treating Post-Traumatic Stress Disorder” generally relates to methods for treating the symptoms of post-traumatic stress disorder (PTSD) that include applying one or more electrical impulses transcutaneously to the vagus nerve for approximately 90 seconds to approximately 3 minutes.
- The electrical impulses may comprise bursts of 2 to 20 pulses.
Retrieved on:
Tuesday, December 26, 2023
ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
Key Points:
- ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
- The two patents were issued on December 26, 2023, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
US Patent No.
- 11,850,056 entitled “Devices and Methods for Remote Therapy and Patient Monitoring” generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a heart rate variability (HRV) of the patient, and comparing the HRV with data related to parameters of the therapy regimen.
- US Patent No.
